Vir Biotechnology, Inc.
HealthcareNASDAQ:VIR · NASDAQ Global Select
+$0.09 today
Vol 1.11M · Avg 1.88M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $276.1M |
| Short-term Investments | $196.3M |
| Other Current | $50.6M |
| Total Current Assets | $523.0M |
| PP&E (Net) | $113.9M |
| Goodwill | $16.9M |
| Intangible Assets | $7.8M |
| Long-term Investments | $333.0M |
| Other Non-current | $31.0M |
| Total Non-current Assets | $502.6M |
| Total Assets | $1.0B |
Analysis
Selected assets total $1.0B for Latest. The largest visible component is Long-term Investments at $333.0M, about 32.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $234.1M +5.0% | $222.9M -7.7% | $241.6M -71.5% | $848.6M +144.0% | $347.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $228.8M -66.5% | $682.4M -46.7% | $1.3B -17.5% | $1.6B +331.1% | $360.3M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $3.6M | $0 | $0 | $0 -100.0% | $773.1M | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $47.6M -65.3% | $137.1M +108.3% | $65.8M +11.2% | $59.2M +588.8% | $8.6M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $514.1M -50.7% | $1.0B -34.4% | $1.6B -37.0% | $2.5B +61.2% | $1.6B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $117.7M -4.2% | $122.9M -26.5% | $167.2M -11.1% | $188.2M +44.7% | $130.1M | $1.2B | $1.5B | $687.8M |
| Goodwill | $16.9M +0.0% | $16.9M +0.0% | $16.9M +0.0% | $16.9M +0.0% | $16.9M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $7.8M -3.1% | $8.1M -64.1% | $22.6M -31.1% | $32.8M -1.6% | $33.3M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $314.6M +65.6% | $190.0M +80.5% | $105.3M +340.0% | $23.9M -88.1% | $201.4M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 -100.0% | $249.7M | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $31.7M +71.9% | $18.4M -2.3% | $18.9M +108.3% | -$228.5M -2436.1% | $9.8M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $488.7M +37.2% | $356.3M +7.7% | $330.8M +16.9% | $283.0M -27.7% | $391.4M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $1.0B -28.3% | $1.4B -27.1% | $1.9B -31.5% | $2.8B +43.4% | $2.0B | $13.3B | $11.9B | $10.6B |
| Account Payables | $9.8M +92.9% | $5.1M -19.8% | $6.3M -1.4% | $6.4M -1.5% | $6.5M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $8.8M | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 -100.0% | $149.0K -99.0% | $15.2M +144.9% | $6.2M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 -100.0% | $12.6M -80.5% | $64.9M +317.9% | $15.5M -84.2% | $98.2M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $74.2M +362.1% | $16.1M +71.7% | $9.4M +22.2% | $7.7M | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $92.8M -22.4% | $119.7M -31.8% | $175.4M -65.7% | $511.0M +49.8% | $341.2M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $89.1M | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 -100.0% | $3.3M -82.4% | $18.4M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 -100.0% | $1.5M -97.1% | $53.2M +1294.7% | $3.8M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | -$33.4M -186.4% | $38.6M -4.0% | $40.2M +22.6% | $32.8M +29.3% | $25.4M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $144.7M +12.4% | $128.8M -16.1% | $153.4M -28.0% | $213.1M +17.6% | $181.2M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $237.5M -4.4% | $248.4M -24.4% | $328.8M -54.6% | $724.1M +38.6% | $522.4M | $14.7B | $3.7B | $9.6B |
| Common Stock | $14.0K +0.0% | $14.0K +7.7% | $13.0K +0.0% | $13.0K +0.0% | $13.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.2B -57.6% | -$759.8M -219.5% | -$237.8M -163.0% | $377.2M +372.2% | -$138.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$2.1M -19.8% | -$1.7M -110.7% | -$815.0K +91.1% | -$9.1M -730.0% | -$1.1M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $765.3M -33.5% | $1.2B -27.7% | $1.6B -23.5% | $2.1B +45.1% | $1.4B | $9.1B | $7.7B | $3.3B |
| Total Debt | $186.9M +90.9% | $97.9M -21.4% | $124.5M -2.7% | $128.0M -6.9% | $137.5M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$47.2M +62.3% | -$125.1M -6.9% | -$117.0M +83.8% | -$720.7M -242.6% | -$210.3M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
Geron Corporation
NASDAQ:GERN
$737.75M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
YD Bio Limited Ordinary Shares
NASDAQ:YDES
$231.62M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$212.27M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does VIR have?
Vir Biotechnology, Inc. (VIR) reported $234.11M in cash and equivalents in fiscal 2025.
How much debt does VIR carry?
Vir Biotechnology, Inc. (VIR) reported $186.91M of total debt, with net debt of -$47,201,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.